|
Trident Pharmaceuticals Announces Initiation of Phase 1a Clinical Study of HF1020
MarketWatch (press release) HF1020 is believed to offer a novel approach for treating the underlying inflammatory pathology of autoimmune disease and allergic asthma, without causing systemic immunosupression. HF1020 is an oral biopharmaceutical product which acts by inducing … |
View full post on asthma – Google News